to Guide Clinical
Our reporting algorithms empower laboratories with comprehensive and flexible product offerings to expand their services.
Pharmacogenomic (PGx) Services
Coriell Life Sciences delivers actionable reports and interpretations of clinical laboratory pharmacogenomic results. Coriell Life Sciences PGx reports evaluate genetics in concert with other medication-associated risks to improve patient health to provide a complete, personalized picture of medication safety.
Take advantage of the fact that genetics doesn’t change over a patient’s lifetime to address issues of polypharmacy, medication efficacy, peri-operative care, and pain management.
GeneDose: Comprehensive Polypharmacy Interpretation and Reporting
Born from the personalized medicine research study at the Coriell Institute for Medical Research where the landmark, peer-reviewed PhAESIS process1 for evidence evaluation was created, Coriell Life Sciences’ GeneDose PGx Report provides comprehensive, clinically-relevant and scientifically-rigorous results for pharmacogenomic and medication safety reporting.
GeneDose LIVE: Real-Time Decision-Support Modeling
Coriell Life Sciences PGx reporting goes well beyond simply providing a static document to physicians by supporting the CLS GeneDose LIVE real-time medication decision support and modeling too. Quickly see which medications are wrong for patients and audition alternatives for safer therapy, all in real time.
GeneDose LIVE also provides risk analysis of non-genetic factors. Lifestyle, drug-drug interactions, age-related risks, FDA warnings, and more are all assessed in real-time.
Opioid Appropriateness Reporting
To appropriately address clinical pain management, Coriell Life Sciences tackles the issues of medication safety, efficacy, and Opioid Use Disorder predilection in a single, actionable report, comprised of:
- Analgesic Appropriateness Report – determine the most appropriate pain medication, opioid or not, for an individual, based on their DNA
- Coriell Life Sciences Addiction Predilection (CAP) Score – receive a quantitative measure of a patient’s likelihood of developing Opioid Use Disorder
Anti-ADHD Medication Appropriateness Reporting
Provides recommendations for, and against, the use of specific ADHD medications, based on the patient’s DNA. Decrease the time to getting these important therapies correct.
Cardiology Medication Appropriateness Reporting
Perfect for cardiologists and primary care physicians, CLS offers a comprehensive analysis of a patient’s medications to help clinicians determine which are best suited for a given patient. Risks associated with polypharmacy in the cardiac patient include drug-drug interactions, anticholinergic burden, age- and pregnancy-related concerns, FDA warnings, food and drink interactions, and genetics. Improving a patient’s treatment plan decreases hospital and emergency department visits, decreases healthcare costs, and improves their quality of life.
Behavioral Health Medication Appropriateness Reporting
This Coriell Life Sciences report takes a comprehensive look at medications used to treat depression, anxiety, ADHD, and other psychiatric health concerns and provides recommendations guided by an individual’s pharmacogenomic profile.
Perioperative & Surgical Reporting
- Malignant hyperthermia (MH) diagnosis and medications to avoid
- Pain management medication appropriateness, including predilection for Opioid Use Disorder
- Post-operative nausea and vomiting medication appropriateness and recommendations
Malignant Hyperthermia (MH) Report
Available alone or as part of the Perioperative Medication Appropriateness Report, this CLS MH report details a patient’s genetic predisposition to malignant hyperthermia and suggests the classes of anesthetics that would be most safe and appropriate.
Cannabinoid Receptor Report
Results from certain CNR1 & 2 gene SNP variants can be reported. No clinically-relevant, outcomes based on interpretations are yet provided.
Infectious Disease Testing - Molecular Diagnostics
Coriell Life Sciences delivers actionable reports and interpretations of clinical laboratory infectious disease and antibiotic resistance testing. The CLS Infectious Disease Report interprets semi-quantitative laboratory assays of pathogenic microorganisms and, in concert with antibiotic resistance testing, provides antibiotic treatment options.
CLS Infectious Disease Reports provide a list of useful medications to aid in decision support and rapid treatment of UTI, skin, fungal, and respiratory infections.
Women’s Health Interpretation & Reporting
The comprehensive Women’s Health Report provides a differential diagnoses of Bacterial Vaginosis (BV), Yeast Infection*, and Trichomoniasis (Trich) Infections* with increased specificity and sensitivity2. Treatment options based on diagnosis, history of recurrence, and pregnancy status are included to assist in rapid prescription decision making.
This report can also include Anaerobic Vaginosis (AV) and Sexually Transmitted Infections (STIs)*
*Also available for men.
Urinary Tract Infection Reporting
Culture methods are slow and even unavailable for some microbes. This molecular diagnostic report provides identification of pathogenic organisms to guide rapid therapeutic decisions in the clinic. Further reporting on the presence of antibiotic resistance genes in the sample guide improved, personalized treatment.
Respiratory Pathogen Testing
This diagnostic assay can quickly diagnose multiple respiratory ailments including SARS, pneumonia, and TB from a single sample.
A variety of dermatological and systemic fungal infections can be identified with this assay.
Wound Healing Reporting
This report looks at the microbiome of hard-to-manage wounds; especially prevalent among elderly and diabetic patients. In addition to evaluation of the wound itself, the report provides insight into issues of antibiotic resistance. The resulting diagnostic report includes recommendations for medications for treatment decision-making.
1The Coriell Personalized Medicine Collaborative Pharmacogenomics Appraisal, Evidence Scoring and Interpretation System, Genome Medicine, October 2013. Gharani, N; Keller, MA; Stack, CB; Hodges, LM; Schmidlen, TJ; Lynch, DE; Gordon, ES; Christman, MF.
2Diagnosing Bacterial Vaginosis with a Novel, Clinically-Actionable Molecular Diagnostic Tool. J Appl Microb Res. Vol: 1, Issue: 2 (01-08). Jarvis JP, Rains D, Kradel SJ, Elliott J, Diamond EE, Avaniss-Aghajani E, Yasharpour F, Shaman JA (2018)
Let's Get Started
Do you want to control your healthcare spend while improving the health and satisfaction of your members? Contact us to find out how much you could save.
Call (888) 415-7834 – or let us know below how we can reach you, and we’ll be in touch.